Literature DB >> 2584710

The role of the Ia-invariant chain complex in the posttranslational processing and transport of Ia and invariant chain glycoproteins.

S Simonis1, J Miller, S E Cullen.   

Abstract

The invariant chain (Ii) is a nonpolymorphic glycoprotein that associates with the Ia alpha- and beta-chains of MHC class II Ag during their transport to the cell surface. Although surface expression of Ia can occur in the absence of Ii, it has not been shown whether the intracellular association of Ia and Ii affects the biosynthetic rate or specificity of posttranslational modifications to the individual molecules. Analysis of transfected cell lines carrying either Ia, Ii, or both Ia and Ii demonstrated efficient assembly of alpha-beta whether or not Ii was present. Pulse-chase studies and two-dimensional gel electrophoresis showed that Ii did not affect the addition of Ia N-linked oligosaccharide chains, or the extent or rate of their conversion to the complex form, nor did it affect the sulfation of alpha and beta glycoproteins. Ii also did not affect the rate of Ia synthesis or appearance of Ia at the cell surface. In contrast, Ia dramatically affected the posttranslational modification of Ii. Although invariant chain was modified by addition of fatty acid, N-linked oligosaccharide, and glycosaminoglycan in the absence of Ia, the processing of Ii-linked oligosaccharide into more acidic, terminally glycosylated forms was significantly less when Ia was absent, and although conversion to proteoglycan did occur, the glycosaminoglycan chains were significantly shorter than normal. The disappearance of radiolabel from the 31,000 Da form of Ii was faster when Ia was present, and the processing of Ii was more rapid when it was associated with Ia. Thus, the rate and manner in which Ii enters and passes through the Golgi is critically affected by Ia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2584710

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules.

Authors:  M S Anderson; J Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  Invariant chain promotes egress of poorly expressed, haplotype-mismatched class II major histocompatibility complex A alpha A beta dimers from the endoplasmic reticulum/cis-Golgi compartment.

Authors:  C Layet; R N Germain
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

3.  Invariant chain targets HLA class II molecules to acidic endosomes containing internalized influenza virus.

Authors:  C A Lamb; J W Yewdell; J R Bennink; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

4.  Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts.

Authors:  L Kopper; A Bankfalvi; R Mihalik; T T Glant; J Timar
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Relationship between invariant chain expression and major histocompatibility complex class II transport into early and late endocytic compartments.

Authors:  P Romagnoli; C Layet; J Yewdell; O Bakke; R N Germain
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

6.  Invariant chain trimers are sequestered in the rough endoplasmic reticulum in the absence of association with HLA class II antigens.

Authors:  M S Marks; J S Blum; P Cresswell
Journal:  J Cell Biol       Date:  1990-09       Impact factor: 10.539

7.  Mouse B lymphocyte specific endocytosis and recycling of MHC class II molecules.

Authors:  J Salamero; M Humbert; P Cosson; J Davoust
Journal:  EMBO J       Date:  1990-11       Impact factor: 11.598

8.  Inhibition of invariant chain (Ii)-calnexin interaction results in enhanced degradation of Ii but does not prevent the assembly of alpha beta Ii complexes.

Authors:  P Romagnoli; R N Germain
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.